XVIVO Perfusion breaks new ground in Germany and Texas

The first XPS™ in Europe is going to be delivered to Germany and the first XPS™
is delivered to the densely populated Texas in the USA. Installation and
training will take place during the month of February in both these clinics.
XVIVO Perfusion’s XPS™ has been approved by FDA in the USA for the evaluation of
marginal lungs before lung transplantation and has received a CE mark in Europe.
XPS™ is used with good clinical results at leading clinics in the USA and there
is already one at a clinic in Asia. In Europe, EVLP using STEEN Solution™ was
previously done manually, in other words without XPS™. Access to XPS™ enables
EVLP to be standardized and simplified. There is now great interest in XPS™ in
both the USA and in Europe. Further university hospitals in Europe and the USA
plan to start using EVLP (lung evaluation) combined with XPS™ and STEEN
Solution™.

“The first XPS™ for Europe is an important milestone for XVIVO Perfusion and we
are very pleased that Europe is now part of the expansion of EVLP using XPS™ and
STEEN Solution™. This is a big step forward in being able to save more patients
with terminal lung disease and give them a new life,” says Magnus Nilsson, CEO
of XVIVO Perfusion.

February 4, 2015
Gothenburg
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +46 31 788 21 59,
christoffer.rosenblad@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the
company’s website, www.xvivoperfusion.com

The information was submitted for publication on February 4, 2015 at 8:30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB is a medical technology company which develops solutions and
systems for assessing and preserving organs outside the body and for selecting
usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the
USA. The XVIVO share is listed on NASDAQ OMX First North and has the ticker
symbol XVIVO. More information can be found on the website
www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity
number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com